2011
Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. The Journal Of Clinical Psychiatry 2011, 73: 121-8. PMID: 21939611, PMCID: PMC4040971, DOI: 10.4088/jcp.10m06574.Peer-Reviewed Original ResearchConceptsCaregiver Distress ScaleCaregivers of patientsSecond-generation antipsychoticsCaregiver burdenExperiences of caregiversAlzheimer's diseaseBurden InterviewDisease trialsNeuropsychiatric Inventory Caregiver Distress ScaleDistress ScaleCATIE-AD trialAtypical antipsychotic treatmentUsual care settingsAtypical antipsychotic drugsClinical Antipsychotic TrialsSymptoms of psychosisBeck Depression InventoryAD outpatientsTreat analysisAtypical antipsychoticsAntipsychotic treatmentAD patientsAntipsychotic drugsAntipsychotic TrialsCare settings
2010
Family outcomes
Perlick D, Kaczynski R, Rosenheck R. Family outcomes. 2010, 133-155. DOI: 10.1017/cbo9780511712265.009.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsFamily outcomesDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisClinicians
2009
Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial
Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial. Schizophrenia Research 2009, 116: 118-125. PMID: 19864114, DOI: 10.1016/j.schres.2009.09.026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAttitude to HealthCaregiversCost-Benefit AnalysisDouble-Blind MethodFamilyFemaleHumansLongitudinal StudiesMaleMiddle AgedPsychiatric Status Rating ScalesQuality of LifeRegression AnalysisSchizophreniaSchizophrenic PsychologySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsSecond-generation antipsychoticsSecond-generation drugsFamily burdenTreatment assignmentInitial treatment assignmentSecond-generation medicationsClinical Antipsychotic TrialsEvidence of superiorityMedication changesCATIE trialInitial medicationPatient's symptomsAntipsychotic medicationAntipsychotic TrialsDaily livingFamily caregiversService useSide effectsMedicationsSecondary analysisPatientsIntervention effectivenessBurden factorsTrialsAntipsychotics
2006
Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia
Perlick D, Rosenheck R, Kaczynski R, Swartz M, Cañive J, Lieberman J. Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia. Psychiatric Services 2006, 57: 1117-1125. PMID: 16870962, DOI: 10.1176/ps.2006.57.8.1117.Peer-Reviewed Original ResearchConceptsMedication side effectsQuality of lifeDaily livingService useSide effectsAcute inpatient phaseImpact of symptomsPatient problem behaviorsClinical Antipsychotic TrialsPatient's symptomsCaregiver burdenInpatient phaseAntipsychotic TrialsFamily burdenFamily caregiversCaregiver dataPatient behaviorTreatment programPatients' impairmentIncorporation of skillsSymptomsIntervention effectivenessDemographic characteristicsPrevious monthSchizophrenia